1.605
price down icon5.03%   -0.085
after-market Dopo l'orario di chiusura: 1.57 -0.035 -2.18%
loading
Precedente Chiudi:
$1.69
Aprire:
$1.54
Volume 24 ore:
1.91M
Relative Volume:
1.01
Capitalizzazione di mercato:
$221.94M
Reddito:
-
Utile/perdita netta:
$-45.44M
Rapporto P/E:
-4.5857
EPS:
-0.35
Flusso di cassa netto:
$-42.28M
1 W Prestazione:
-23.57%
1M Prestazione:
-41.21%
6M Prestazione:
-15.53%
1 anno Prestazione:
-13.24%
Intervallo 1D:
Value
$1.53
$1.695
Intervallo di 1 settimana:
Value
$1.33
$2.435
Portata 52W:
Value
$0.765
$4.08

Compass Therapeutics Inc Stock (CMPX) Company Profile

Name
Nome
Compass Therapeutics Inc
Name
Telefono
617-500-8099
Name
Indirizzo
80 GUEST STREET, BOSTON
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
CMPX's Discussions on Twitter

Confronta CMPX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CMPX
Compass Therapeutics Inc
1.605 221.94M 0 -45.44M -42.28M -0.35
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 66.76B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-24 Iniziato Guggenheim Buy
2025-02-19 Iniziato Piper Sandler Overweight
2024-12-23 Iniziato D. Boral Capital Buy
2024-11-15 Downgrade Leerink Partners Outperform → Market Perform
2024-09-16 Aggiornamento Ladenburg Thalmann Neutral → Buy
2023-01-31 Iniziato Jefferies Buy
2023-01-27 Iniziato Stifel Buy
2022-05-23 Ripresa H.C. Wainwright Buy
2022-03-15 Iniziato Ladenburg Thalmann Buy
2022-01-19 Iniziato B. Riley Securities Buy
2021-12-22 Iniziato Raymond James Outperform
2021-12-20 Iniziato SVB Leerink Outperform
2021-12-15 Iniziato Wedbush Outperform
Mostra tutto

Compass Therapeutics Inc Borsa (CMPX) Ultime notizie

pulisher
Apr 02, 2025

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Leerink Partners Upgrades Compass Therapeutics (CMPX) - Nasdaq

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics rises on trial win for biliary tract cancer therapy - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Leerink raises Compass Therapeutics stock rating, PT to $6 from $4 - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics And 2 More Compelling Penny Stocks - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics Target of Unusually Large Options Trading (NASDAQ:CMPX) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics (NASDAQ:CMPX) Given Outperform Rating at Wedbush - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics price target raised to $11 from $10 at Stifel - MSN

Apr 01, 2025
pulisher
Apr 01, 2025

Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Clinical Breakthrough Propels Compass Therapeutics (CMPX) Stock Higher - Stocks Telegraph

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics Reports Positive Phase 2/3 Trial Results For Tovecimig - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics touts trial success in biliary tract cancer, but more data are needed - Endpoints News

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics stock down amid trial win (CMPX:NASDAQ) - Seeking Alpha

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics stock rises on trial win (CMPX:NASDAQ) - Seeking Alpha

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics Reports Positive Phase 2/3 Trial Results - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer - The Manila Times

Apr 01, 2025
pulisher
Mar 31, 2025

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Mar 31, 2025
pulisher
Mar 31, 2025

Compass Therapeutics to Host Webcast Highlighting Top-Line - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - The Manila Times

Mar 31, 2025
pulisher
Mar 30, 2025

Compass Therapeutics, Inc.'s (NASDAQ:CMPX) market cap decline of US$44m may not have as much of an impact on institutional owners after a year of 0.5% returns - simplywall.st

Mar 30, 2025
pulisher
Mar 27, 2025

Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5? - Yahoo

Mar 27, 2025
pulisher
Mar 25, 2025

Connor Clark & Lunn Investment Management Ltd. Trims Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World

Mar 25, 2025
pulisher
Mar 21, 2025

[Top 3] Best Biotech Penny Stocks to Buy in 2025Finbold - Finbold - Finance in Bold

Mar 21, 2025
pulisher
Mar 21, 2025

10 Hot Biotech Stocks Under $5 - Insider Monkey

Mar 21, 2025
pulisher
Mar 18, 2025

With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest - Yahoo Canada Finance

Mar 18, 2025
pulisher
Mar 18, 2025

Gallbladder Neoplasms Treatment Market Size in the 7MM - openPR

Mar 18, 2025
pulisher
Mar 13, 2025

Compass Therapeutics (CMPX) Projected to Post Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 08, 2025

Rubicon Technology (NASDAQ:RBCN) Now Covered by Analysts at StockNews.com - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to Hold - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Mar 08, 2025
pulisher
Mar 06, 2025

Repligen (NASDAQ:RGEN) and Compass Therapeutics (NASDAQ:CMPX) Critical Review - Defense World

Mar 06, 2025
pulisher
Mar 03, 2025

Research Analysts Issue Forecasts for CMPX Q1 Earnings - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 02, 2025
pulisher
Mar 01, 2025

Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Mar 01, 2025
pulisher
Feb 28, 2025

D. Boral Capital Reiterates "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Compass Therapeutics (NASDAQ:CMPX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Compass Therapeutics shares rise on pipeline progress By Investing.com - Investing.com Canada

Feb 28, 2025
pulisher
Feb 28, 2025

Compass Therapeutics shares rise on pipeline progress - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Compass Therapeutics Reports 2024 Financial Results - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Compass Therapeutics reports Q4 EPS (11c), consensus (9c) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Compass Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

D. Boral Capital Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX) - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Guggenheim - MarketBeat

Feb 26, 2025
pulisher
Feb 24, 2025

Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation - Nasdaq

Feb 24, 2025
pulisher
Feb 24, 2025

Compass stock gains amid Guggenheim buy rating - MSN

Feb 24, 2025

Compass Therapeutics Inc Azioni (CMPX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Capitalizzazione:     |  Volume (24 ore):